XML 49 R26.htm IDEA: XBRL DOCUMENT v3.20.4
Employee Benefit Plans and Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of Intrinsic Value of Options Exercised and Fair Value of Options Vested
The total intrinsic value of stock options exercised as of the date of exercise was as follows:
 Twelve Months Ended
December 31,
(In millions)202020192018
Intrinsic value of options exercised$7.9 $7.4 $30.0 
Schedule of Restricted Stock Units Activity A summary of our RSU activity for the twelve months ended December 31, 2020, 2019 and 2018 is as follows:
(In millions except weighted average grant date fair value)SharesWeighted 
Average
Grant Date
Fair Value
Aggregate
Intrinsic Value
Nonvested at December 31, 20172.7 $70.68 
Granted1.7 66.07 
Vested(1.4)68.44 
Forfeited(0.3)68.56 
Nonvested at December 31, 20182.7 69.19 $319.0 
Granted0.7 144.37 
Vested(1.4)69.45 
Forfeited(0.2)83.45 
Nonvested at December 31, 20191.8 96.63 392.0 
Granted0.5 300.36 
Vested(1.0)92.07 
Forfeited(0.1)137.44 
Nonvested at December 31, 20201.2 $183.51 $430.6 
Schedule of Stock Options Reserved for Future Issuance
Shares of common stock reserved for future issuance were as follows as of the dated indicated:
 December 31,
(In millions)20202019
Stock awards under our plans:
Unvested restricted stock units1.2 1.8 
Reserved for future grant4.5 4.9 
Employee Stock Purchase Plan0.8 0.9 
Total6.5 7.6 
Schedule of Share-Based Compensation Expenses
The following table summarizes share-based compensation expense related to restricted stock units and employee stock purchases under the ESPP for the twelve months ended December 31, 2020, 2019 and 2018:
 Twelve Months Ended
December 31,
(In millions)202020192018
Cost of sales$14.6 $9.0 $9.2 
Research and development37.8 33.5 33.0 
Selling, general and administrative67.0 60.2 59.7 
Total share-based compensation expense$119.4 $102.7 $101.9 
Schedule of Valuation Assumptions for Employee Stock Purchase Plan We estimate the fair value of ESPP purchase rights on the date of grant using the Black-Scholes option pricing model and the assumptions below for the specified reporting periods.
 Twelve Months Ended
December 31,
202020192018
Risk free interest rate
0.13 - 0.95
1.72 - 2.55
1.55 - 2.25
Dividend yield— %— %— %
Expected volatility of Dexcom common stock
0.51 - 0.63
0.40 - 0.51
0.50 - 0.67
Expected life (in years)0.511